Skip to main content
Top

02-12-2017 | Breast cancer | Article

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

Journal: Breast Cancer Research and Treatment

Authors: B. Pistilli, T. Pluard, A. Urruticoechea, D. Farci, A. Kong, T. Bachelot, S. Chan, H. S. Han, G. Jerusalem, P. Urban, D. Robinson, S. L. Mouhaër, E. D. Tomaso, C. Massacesi, C. Saura

Publisher: Springer US

Abstract

Purpose

A Phase Ib study in patients with trastuzumab-resistant, human epidermal growth factor receptor-2- (HER2)-positive advanced breast cancer defined the recommended Phase II dose of buparlisib as 100 mg/day in combination with 2 mg/kg weekly trastuzumab, and reported preliminary signs of clinical activity. Here we present results from the Phase II portion.

Methods

Patients with trastuzumab-resistant, HER2-positive advanced breast cancer received buparlisib plus trastuzumab. Study endpoints included safety/tolerability and antitumour activity. The study was extended to include a Phase Ib dose-escalation phase, in which patients with progressive brain metastases also received capecitabine.

Results

In the Phase II portion, of 50 patients treated with buparlisib and trastuzumab, the most common (≥ 30%) all-grade adverse events (AEs) were diarrhoea (54%), nausea (48%), decreased appetite, increased alanine aminotransferase (36% each), increased aspartate aminotransferase (34%), fatigue, rash (32% each), cough and hyperglycemia (30% each). One (2%) patient achieved complete response and four (8%) patients had confirmed partial responses [PR; including two patients with phosphatidylinositol 3-kinase (PI3 K) pathway-activated tumours]. Overall response rate (ORR) was 10%: the primary endpoint (ORR ≥ 25%) was therefore not met. In the Phase Ib portion, all patients with measurable brain lesions at baseline showed tumour shrinkage to some degree; due to low enrollment, maximum tolerated dose of buparlisib in combination with trastuzumab and capecitabine was not determined.

Conclusion

Buparlisib plus trastuzumab, as a chemotherapy-free regimen, demonstrated an acceptable safety profile but limited efficacy in patients with heavily pretreated, trastuzumab-resistant HER2-positive breast cancer, and in patients with progressive brain metastases also receiving capecitabine.
Literature
1.
Shah S, Chen B (2011) Testing for HER2 in breast cancer: a continuing evolution. Patholog Res Int. 2011:903202. https://​doi.​org/​10.​4061/​2011/​903202
2.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182CrossRefPubMed
3.
Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792. https://​doi.​org/​10.​1056/​NEJM200103153441​101 CrossRefPubMed
4.
Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726. https://​doi.​org/​10.​1200/​JCO.​2002.​20.​3.​719 CrossRefPubMed
5.
Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743. https://​doi.​org/​10.​1056/​NEJMoa064320 CrossRefPubMed
6.
Johnston S, Pippen J Jr, Pivot X et al (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538–5546. https://​doi.​org/​10.​1200/​JCO.​2009.​23.​3734 CrossRefPubMed
7.
Baselga J, Cortés J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109–119. https://​doi.​org/​10.​1056/​NEJMoa1113216 CrossRefPubMed
8.
Swain SM, Baselga J, Kim S-B et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724–734. https://​doi.​org/​10.​1056/​NEJMoa1413513 CrossRefPubMedPubMedCentral
9.
Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791. https://​doi.​org/​10.​1056/​NEJMoa1209124 CrossRefPubMedPubMedCentral
10.
Krop IE, Kim SB, Gonzalez-Martin A et al (2014) Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 15:689–699. https://​doi.​org/​10.​1016/​S1470-2045(14)70178-0 CrossRefPubMed
11.
Baselga J, Gelmon KA, Verma S et al (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138–1144. https://​doi.​org/​10.​1200/​JCO.​2009.​24.​2024 CrossRefPubMedPubMedCentral
12.
Bendell JC, Domchek SM, Burstein HJ et al (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972–2977. https://​doi.​org/​10.​1002/​cncr.​11436 CrossRefPubMed
13.
Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW (2008) Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 112:2359–2367. https://​doi.​org/​10.​1002/​cncr.​23468 CrossRefPubMed
14.
Berns K, Horlings HM, Hennessy BT et al (2007) A functional genetic approach identifies the PI3 K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395–402. https://​doi.​org/​10.​1016/​j.​ccr.​2007.​08.​030 CrossRefPubMed
15.
Nagata Y, Lan KH, Zhou X et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117–127. https://​doi.​org/​10.​1016/​j.​ccr.​2004.​06.​022 CrossRefPubMed
16.
O’Brien NA, Browne BC, Chow L et al (2010) Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 9:1489–1502. https://​doi.​org/​10.​1158/​1535-7163.​MCT-09-1171 CrossRefPubMed
17.
Wang L, Zhang Q, Zhang J et al (2011) PI3 K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 11:248. https://​doi.​org/​10.​1186/​1471-2407-11-248 CrossRefPubMedPubMedCentral
18.
Chakrabarty A, Bhola NE, Sutton CR et al (2012) Trastuzumab-resistant cells rely on a HER2-PI3 K-FoxO-survivin axis and are sensitive to PI3 K inhibitors. Cancer Res 73:1190–1200. https://​doi.​org/​10.​1158/​0008-5472.​CAN-12-2440 CrossRefPubMedPubMedCentral
19.
O’Brien NA, McDonald K, Tong L et al (2014) Targeting PI3 K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res 20:3507–3520. https://​doi.​org/​10.​1158/​1078-0432.​CCR-13-2769 CrossRefPubMed
20.
Andre F, O’Regan R, Ozguroglu M et al (2014) Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15:580–591. https://​doi.​org/​10.​1016/​S1470-2045(14)70138-X CrossRefPubMed
21.
Maira SM, Pecchi S, Huang A et al (2012) Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 11:317–328. https://​doi.​org/​10.​1158/​1535-7163.​MCT-11-0474 CrossRefPubMed
22.
Maira M, Schnell C, Lollini P et al (2012) Preclinical and preliminary clinical activity of NVP-BKM120, an oral pan-class I PI3 K inhibitor, in the brain. ESMO meeting abstracts; (Suppl 15): 1675 (abstract)
23.
Nanni P, Nicoletti G, Palladini A et al (2012) Multiorgan metastasis of human HER-2(+) breast cancer in Rag2(−/−);Il2rg(−/−) mice and treatment with PI3 K inhibitor. PLoS ONE 7:e39626. https://​doi.​org/​10.​1371/​journal.​pone.​0039626 CrossRefPubMedPubMedCentral
24.
Saura C, Bendell J, Jerusalem G et al (2014) Phase Ib study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy. Clin Cancer Res 20:1935–1945. https://​doi.​org/​10.​1158/​1078-0432.​CCR-13-1070 CrossRefPubMed
25.
Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16:606–613CrossRefPubMedPubMedCentral
26.
Spitzer RL, Kroenke K, Williams JB, Löwe B (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166:1092–1097. https://​doi.​org/​10.​1001/​archinte.​166.​10.​1092 CrossRefPubMed
27.
Rodon J, Brana I, Siu LL et al (2014) Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-class I PI3 K inhibitor, in patients with advanced solid tumors. Invest New Drugs 32:670–681. https://​doi.​org/​10.​1007/​s10637-014-0082-9 CrossRefPubMed
28.
Foukas LC, Claret M, Pearce W et al (2006) Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441:366–370. https://​doi.​org/​10.​1038/​nature04694 CrossRefPubMed
29.
Baselga J, Cortes J, Im SA, Clark E, Ross G, Kiermaier A, Swain SM et al (2014) Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 32:3753–3761. https://​doi.​org/​10.​1200/​JCO.​2013.​54.​5384 CrossRefPubMed
30.
Andre F, Hurvitz S, Fasolo A et al (2016) Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3. J Clin Oncol 34:2115–2124. https://​doi.​org/​10.​1200/​JCO.​2015.​63.​9161 CrossRefPubMed